Medtronic reports strongest annual revenue growth in a decade

Medtronic has reported full gross of $36.4bn successful fiscal twelvemonth 2026 (FY26), a fig the institution said reflects the highest yearly maturation achieved successful 10 years.

With FY26 gross indicative of a year-over-year (YoY) emergence of 8.4%, Med-ABtronic expects FY27 maturation to autumn successful 6.75% to 7.25% scope connected an integrated basis, with net mooted to autumn successful the $5.90 to $6.00 per stock range.

The medtech giant’s cardiovascular portfolio, which includes the PulseSelect pulsed-field ablation (PFA) system, was its strongest performing concern conception successful FY26, with gross astir $13.98bn, denoting a 12% uptick YoY.

Meanwhile, Medtronic’s Neuroscience and MedSurg concern lines came successful astatine astir $10.3bn and $8.8bn, corresponding to YoY uplifts of 4.5% and 4.9%, respectively.

Alongside its FY26 financials, Medtronic besides reported its Q4 FY26 results, achieving full gross of $9.81bn. The fig bushed analysts’ estimates of $9.63bn, ​according to information compiled by the London Stock Exchange Group (LSEG) and seen by Reuters. The full besides bested Medtronic’s Q3 FY26 show by astir $800m.

In Q4, Medtronic’s cardiovascular concern grew 13.8% YoY to astir $3.8bn, portion Neuroscience and MedSurg saw YoY maturation of 5% and 8% to astir $2.75bn and $2.39bn, respectively.

Medtronic’s fiscal results sent its stock terms connected the New York Stock Exchange (NYSE) up by much than 5% to $77.89 astatine marketplace unfastened connected 3 June, versus a anterior adjacent of $73.75. Medtronic has a marketplace headdress of $94.69bn.

Geoff Martha, Medtronic president and CEO, said: "Our show reflects the strongest yearly top-line maturation Medtronic has delivered successful 10 years, powered by disciplined execution crossed our portfolio and continued operational rigour.

"These results correspond the compounding interaction of deliberate choices we've made to fortify our strategy, sharpen execution, and put successful the areas that volition thrust our future. We saw continued spot successful immoderate of our largest businesses similar CRM, CST and Surgical, and we are gathering momentum successful our highest maturation opportunities, specified arsenic Affera, Symplicity, Hugo, Altaviva and Stealth AXiS. Together with the investments we're making successful our pipeline, Medtronic is well-positioned to present sustained maturation and semipermanent value."

"Medtronic reports strongest yearly gross maturation successful a decade" was primitively created and published by Medical Device Network, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.